Health Care • Biotechnology: Pharmaceutical Preparations
$11.15 ▼ -0.40
(-3.46%)
MKT CAP: $324.7M • VOL: 218.5K
52W L $10 52W H $17
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$9
MEDIAN
$12
MEAN
$13
HIGH
$15
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ENTA TAPE
ENTA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $13.49 | $12.82 | 2025-02-14 | $10.15 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $14.05 | $13.16 | 2025-02-06 | $10.48 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $12.71 | $12.27 | 2025-01-29 | $10.70 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $11.37 | — | 2025-01-17 | $10.93 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $9.81 | $10.59 | 2025-01-09 | $9.92 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $13.27 | $11.60 | 2024-12-18 | $9.70 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $10.82 | $11.26 | 2024-12-04 | $10.37 | -4.3% | 48% | C |